Use of paracetamol and paracetamol & dexmedetomidine combination for reduction of analgesic requirement and reduction of nausea and vomiting after operation in laparoscopic surgery.

Comparison of paracetamol and paracetamol-dexmedetomidine combination on postoperative pain and postoperative nausea and vomiting after elective laparoscopic hysterectomy surgery: a randomized clinical trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/045086

Enrollment

Registered

2022-08-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N859- Noninflammatory disorder of uterus, unspecified Health Condition 2: N859- Noninflammatory disorder of uterus, unspecified

Interventions

Intervention1: Paracetamol: Paracetamol 4.5mg/kg bolus dose over 15 minutes,then demand dose 1 mg/kg/hr with 30 min lockout interval and continuous dose 0.5 mg/kg/hr Control Intervention1: paracetamol

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA grade I and II 2. Scheduled for laparoscopic gynaecological surgery under general anesthesia

Exclusion criteria

Exclusion criteria: 1.Known allergy to study drugs 2.Use of antiemetic drugs within 24 hrs of surgery 3.Morbid obesity(BMI >40) 4.Chronic use of opioids 5.Patients with hepatic,renal or cardiovascular dysfunction 6.Psychiatric patients

Design outcomes

Primary

Measure	Time frame
VAS Scoring and postoperative analgesic requirementTimepoint: VAS Scoring at 1,2,4,6 and 12th hour and analgesic requirement in first 24 hour	—

Secondary

Measure	Time frame
Postoperative nausea and vomitingTimepoint: 24 hr postoperative period	—

Countries

India

Contacts

Public ContactDr Vinit Kumar Srivastava

Apollo Hospitals Bilaspur

drvinit75@gmail.com9755557539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026